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Abstract: Definitive radiotherapy treatment of thoracic tumors may 
be hampered by poor tumor visualization on radiological imaging 
and the effects of tumor motion. Fiducial markers act to enhance 
tumor visualization and tracking. Traditional solid fiducial markers, 
however, may result in complications, particularly in proximal lung 
lesions. These complications may be mitigated through the use of a 
liquid fiducial marker. This article presents four cases which demon-
strate the feasibility of bronchoscopic delivery of lipiodol as a fidu-
cial marker, to aid in guided radiotherapy for certain lung tumors.
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Lung cancer is a leading cause of global cancer death.1 Radiotherapy provides a definitive treatment option for 
lung tumors which are not amenable to surgical resection, or 
in patients who would not tolerate an operative procedure.2 
Optimal treatment requires delivery of maximal radiation to 
the target volume, whilst minimizing dose to normal tissues. 
This accurate targeting of lung masses is achieved principally 
through localization through radiographic imaging with com-
puted tomography (CT).
Combined fluoro-deoxyglucose positron emission 
tomography (FDG PET) and CT imaging improves the accu-
racy of target volume definition.3 This, however, may not be 
possible for small endobronchial lesions below the limits of 
PET resolution or in PET-negative lesions. In addition, sig-
nificant tumor motion during the respiratory cycle may impair 
accurate targeting of lesions. This can be particularly problem-
atic in mobile peripheral lesions. Respiratory gating ensures 
optimized therapy delivery through the respiratory cycle. This 
technique, however, is still reliant on the spatial resolution of 
kilovoltage onboard imaging devices. Radiopaque fiducials 
can act as surrogate tumor markers to enable accurate respira-
tory gated therapy using onboard image guidance.
Solid fiducial markers (gold seeds or platinum coils) 
implanted in the lung, have been used to localize tumors on 
chest imaging, to assist with tracking tumor motion during 
radiotherapy planning and treatment delivery. However chal-
lenges exist, particularly with regard to fiducial dislodgement 
and migration.4 Although cadaveric series have demonstrated 
the feasibility of endoscopically delivered radio-opaque liquid 
markers to thoracic tumors,5 this has yet to have been explored 
in vivo.
Lipiodol (an iodized poppy-seed oil) displays poten-
tial advantages over traditional materials as a fiducial 
marker in lung lesions. Lipiodol is an inexpensive, readily 
available agent. In addition, subcutaneous liquid adminis-
tration may reduce the risk of fiducial dislodgement and 
migration, particularly in proximal bronchial lesions, 
where insertion of solid fiducial markers has been asso-
ciated with unacceptable rates of marker migration4 and 
major complications.6
In this report, we present our experience with use of 
bronchoscopically administered Lipiodol as a fiducial to 
locate small peripheral malignancies or to highlight tumor 
margins of central airway lesions. We examine its utility in 
improving radiotherapy targeting in the treatment of lung 
masses that may be difficult to localize using traditional image 
guided radiotherapy (IGRT) techniques.
MATERIALS AND METHODS
Lipiodol (Guerbet, Villepinte, France) was used to mark 
both central airway lesions (Figs. 1 and 4) and peripheral lung 
lesions (Figs. 2 and 3). Lipiodol was placed following col-
lection of diagnostic samples; 1 ml lipiodol was drawn up 
directly into the 25-gauge sclerotherapy needle used to deliver 
lipiodol into tissue.
For peripheral lesions, navigation to the site of the lesion 
was achieved using electromagnetic navigation (EMN).7 
Endobronchial ultrasound (EBUS)8 was then used, to con-
firm location of the lesion. A 25-gauge sclerotherapy needle 
was passed through the guide sheath which remained in situ 
after EBUS examination. Fluoroscopy was used to confirm 
the correct position in the lung parenchyma and assess for 
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inadvertent systemic injection; 1 ml lipiodol was then injected 
under fluoroscopic vision.
For bronchoscopically visible lesions, direct visualiza-
tion of the lesion was obtained and the sclerotherapy needle 
was passed through the working channel of the bronchoscope. 
Deployment of the needle into submucosal tissue at the mar-
gin of the lesion was performed under direct vision and 0.5–
1 ml lipiodol was injected.
RESULTS
Case 1
A 65-year-old male, presented with 3 months of pro-
gressive dyspnoea and productive cough. Bronchoscopy dem-
onstrated a partial obstruction of the right upper lobe anterior 
segment by a polypoid endobronchial tumor, which showed 
significant mobility over the respiratory cycle.
FIGURE 1. A, intra-procedural image of endo-
bronchial tumor. (B) Chest radiograph 3 days 
post-procedure demonstrates radio-opaque lipi-
odol stippling. (C) Intra-procedural imageintensi-
fier demonstrates radio-opaque lipiodol marking 
of tumor tissue. (D) Planning computed tomogra-
phy 1 month post-procedure, hyperdensity noted 
at site of lipiodol injection in right upper lobe 
bronchus.
FIGURE 2. A, computed tomography (CT) 
chest pre-bronchoscopy demonstrating left 
upper lobe mass. (B) Chest radiograph post-
procedure demonstrates radio-opaque lipiodol 
stippling at tumor site. (C) CT chest 2 months 
post-procedure demonstrates radio-opaque 
subcutaneous lipiodol marking. (D) CT chest 7 
months post-procedure demonstrates residual 
radio-opaque lipiodol, significant effusion and 
tumor shift also noted.
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PET/CT was unable to visualize the known polyp-
oid tumor. Lipiodol was injected to the tumor site under 
direct vision. Radiopaque foreign material was visual-
ised with CT (Fig. 1D) 1 month post bronchoscopy at the 
site of injection, and the patient was able to complete a 
course of radical radiotherapy guided by the location of 
the lipiodol.
Case 2
An 86-year-old male, presented with a single episode of 
hemoptysis. CT chest identified a mass within the left upper 
lobe. PET/CT demonstrated a left upper lobe mass, measur-
ing 6.7 cm. FDG-avid level 5 and 6 lymph nodes were also 
identified.
He underwent radial EBUS bronchoscopy with 
EMN. Lipiodol was injected at multiple sites subcutane-
ously at the segmental carina of the left upper lobe bron-
chus. The patient went on to receive radical concurrent 
chemoradiotherapy.
Follow-up CT imaging two (Fig. 2C) and seven (Fig. 2D) 
months post bronchoscopy, demonstrated ongoing visible 
high density foreign material at the sites of lipiodol injection.
Case 3
An 84-year-old male presented with a suspected meta-
static left lower lobe lateral basal lung lesion on a background 
of stage III microcystic adnexal carcinoma of the upper lip 
with submandibular lymph node spread.
Surveillance CT scanning subsequently revealed a new 
peripheral left lower lobe lateral basal lung lesion. Lipiodol 
was injected transbronchially to the tumor site using EBUS 
bronchoscopy with EMN. The patient underwent stereotactic 
body radiosurgery in accordance with an institutional study 
protocol.9 Follow-up PET/CT imaging 8 months post lipiodol 
injection (Fig. 3D) noted stable high density foreign material 
in the region of the left lung lesion.
Case 4
A 77-year-old male, investigated for hemoptysis, was 
found to have a tracheal lesion on a background of resected 
non–small-cell lung cancer. Biopsy of a subglottic abnormal-
ity seen at bronchoscopy confirmed tracheal squamous cell 
carcinoma.
PET/CT scan demonstrated FDG avidity at the site of 
the biopsied lesion, but poor visualization of the lesion on 
CT. Narrow band imaging bronchoscopy identified the lesion 
on the anterior aspect of the trachea, just distal to the larynx 
(Fig. 4B). Lipiodol was injected submucosaly into the poles 
of the lesion.
Planning CT imaging 2 weeks post bronchoscopy (Fig. 
4D,E) demonstrated high density foreign material at the site 
of lipiodol injection into the tracheal lesion. The patient went 
on to undergo chemoradiotherapy to a target volume defined 
in part by the injected lipiodol.
DISCUSSION
Lipiodol was developed by Marcel Guerbet in 1901. 
Conceived as a delivery agent for therapeutic iodine, it found 
major success as the first iodinated contrast agent, being used 
in myelography in 1921.10 It went on to see use as a contrast 
agent in hysterosalpingography, but fell out of favor because 
of developments in water soluble contrast agents.10 Evidence, 
however, points to a renewed role for Lipiodol in this area, as a 
therapy in the treatment of endometriosis-related infertility.11
More recently, it has seen use in intra-arterial adjuvant 
therapy post resection of hepatocellular carcinoma.12 It has 
also been used as a fiducial marker (injected intravesically 
during cystoscopy) to guide radiotherapy in the treatment of 
FIGURE 3. A, intra-procedural image intensifier 
demonstrates lipiodol administration through 
sclerotherapy needle. (B) Chest radiograph post-
procedure demonstrates radio-opaque lipiodol 
stippling at tumor site. (C) Planning computed 
tomography (CT) day 1 post bronchoscopy 
demonstrating radio-opaque lipiodol marking at 
tumor site. (D) Follow-up CT 8 months post-
procedure demonstrates ongoing radio-opaque 
lipiodol marking at tumor site.
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bladder wall tumors.13 In the treatment of lung cancer, it has 
been administered as a radio-opaque marker (injected under 
CT guidance) for thoracoscopic surgical resection of lung 
tumors under image intensifier guidance.14
The four cases presented demonstrate the feasibility of 
submucosal or transbronchial injection of lipiodol, through a 
bronchoscopic approach, to lung lesions, as a fiducial marker 
for patients undergoing radiotherapy to thoracic tumors. The 
use of lipiodol for this purpose has not to our knowledge been 
reported previously.
In each case, the lipiodol was effectively delivered to 
the target site through bronchoscopic injection. Delivery to 
lesions in diverse locations throughout the respiratory tract 
was achieved, with successful injection into proximal, periph-
eral, endobronchial, and intra-parenchymal lesions. Lipiodol 
was targeted to the directly/roentgenographically visible tumor 
margins. In this way, it was used to optimize gross tumor 
volume definition. An additional margin was then added dur-
ing radiotherapy planning, forming the clinical target volume. 
The clinical target volume margin is applied to account for 
microscopic spread of tumor cells beyond the gross tumor vol-
ume, and thus the radiation portals encompassed the expected 
pathological extent of disease.
Administration was well tolerated, with no signifi-
cant localized or respiratory complications encountered. 
Bronchoscopically administered lipiodol is delivered using 
instruments that are routinely used during bronchoscopy. When 
used for diagnostic purposes, transbronchial needle aspira-
tion is rarely associated with significant complications.15 We 
believe the same is true for bronchoscopic administration of 
lipiodol through needle injection. Inadvertent vascular injec-
tion is exceedingly unlikely and would be identified immedi-
ately as injection is performed under fluoroscopic vision or 
under direct vision. Furthermore, the rarity of complications 
after intravascular injection in hepatocellular carcinoma16 sug-
gests that the inadvertent systemic delivery of small volumes 
of lipiodol in bronchoscopic delivery would be well tolerated.
Stability of lipiodol at the site of injection and its rela-
tion to the target lesion was noted on follow-up CT imaging. 
The lipiodol was evidenced in situ at up to 8 months (Fig. 3D) 
post injection. For subcutaneous administration, any extra 
lipiodol that did not enter the target lesion was expectorated 
and not noted on follow-up imaging. No migration or extra-
lesional lipiodol was noted in any of the cases.
The tolerability and stability of injected lipiodol in 
these cases is in keeping with previous reports of safe and 
stable intravascular and intravesical lipiodol administration 
for hepatic and urological procedures.12,13 Several advantages 
were noted in the use of lipiodol during these cases. It dem-
onstrates excellent stability at the injection site, it is physi-
ologically inert, and injection into lung/airway lesions does 
not require any equipment not readily available in most bron-
choscopy suites/centers.
There are, however, some issues with use of lipiodol that 
require further refinement to improve its utility. The viscos-
ity makes accurate volume delivery challenging, particularly 
through the long 25-gauge sclerotherapy needle. Although 
this can, to some degree, be estimated visually with fluoros-
copy during injection into peripheral lesions, volume control 
for central lesions is difficult, especially given the transpar-
ency of the solution.
The clinical experience in these cases indicates that 
lipiodol was clearly visible during IGRT and potentially suit-
able as a fiducial marker for radiation therapy. The lipiodol 
was visible using kilovoltage onboard cone-beam imaging. 
This could be used to guide tumor matching before IGRT 
delivery. In the instance of a tumor located within the proxi-
mal bronchi, or in the setting of postoperative irradiation in 
which minimal macroscopic disease burden remains, lipi-
odol could be particularly useful given the lack of suitable 
tumor visualization to guide the IGRT process. In the set-
ting of peripheral lung targets, there is a potential to explore 
lipiodol as a fiducial for respiratory gated treatment deliv-
ery. In order for radiation delivery to be triggered through 
a selected portion of the respiratory cycle, the motion of a 
FIGURE 4. A, Intra-procedural image of the anterior tracheal 
tumor under normal light. (B) Intra-procedural image of the 
anterior tracheal tumor under narrow band imaging. (C) 
Post-procedure chest radiograph demonstrates increased 
opacity in anterior trachea at site of lipiodol injection. Clarity 
of opacity partially obscured by rotation of subject. (D,E) 
Planning computed tomography, 2 weeks post bronchoscopy 
demonstrates increased radio-opacity in the submucosa of 
the anterior trachea at the site of lipiodol injection.
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candidate fiducial would need to be clearly visualized within 
the gating window. However, to be reliably and reproducibly 
visualized, this may require an increased volume of the dye 
to be injected, possibly at multiple sites around the tumor, 
which in itself poses technical challenges given the viscosity 
as previously discussed.
There are clear potential advantages to injected lipiodol 
as a fiducial agent in certain lung lesions. It is especially use-
ful in treatment of central airway lesions that are frequently 
radio-occult, and where use of solid fiducial markers has been 
abandoned because of stability and safety concerns.4 Post-
procedural chest imaging, including plain radiograph and CT 
scanning, demonstrate the ability for injected lipiodol to be 
identified radiographically, and confirm stability for several 
weeks after administration. This is consistent with stability in 
submucosal intravesical lipiodol injection.17
Our preliminary experience confirms the feasibility of 
bronchoscopic administration of lipiodol and provides sup-
port for further assessment of its long-term efficacy, or other 
radio-opaque liquids, in this role. Changes in viscosity of lipi-
odol may improve ease of volume delivery especially in cen-
tral airway lesions.
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